ONCOIMMUNE, INC.;CHILDREN'S NATIONAL MEDICAL CENTER
发明人:
Yang LIU,Pan ZHENG,Martin DEVENPORT
申请号：
US16614660
公开号：
US20200197485A1
申请日:
2018.05.21
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.
